Literature DB >> 25092894

IFNαR signaling in effector but not regulatory T cells is required for immune dysregulation during type I IFN-dependent inflammatory disease.

Shivani Srivastava1, Lisa K Koch2, Daniel J Campbell3.   

Abstract

Type I IFNs are a family of proinflammatory cytokines that are essential for antiviral immunity but whose overexpression is associated with several autoimmune disorders. In this study, we asked how chronic IFN overexpression regulates the activity of different cell types and how this contributes to immune dysfunction during IFN-associated inflammatory diseases. We show that in mice that chronically overproduce type I IFNs owing to loss of the DNA exonuclease Trex1, inflammatory disease completely depends on IFNαR signaling in T cells. Although IFNs directly inhibited the proliferation and activation of Foxp3(+) regulatory T cells, this was neither required nor sufficient for development of inflammatory disease. Rather, chronic IFN expression directly promoted the expansion and activation of effector T cells, and disease development was completely dependent on IFNαR signaling in these cells. Thus, chronic IFN expression can drive inflammatory disease via its direct effects on effector, but not regulatory, T cells.
Copyright © 2014 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25092894      PMCID: PMC4157086          DOI: 10.4049/jimmunol.1401039

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  46 in total

1.  Ulcerative colitis associated with interferon treatment for chronic hepatitis C.

Authors:  C Mavrogiannis; I S Papanikolaou; I S Elefsiniotis; D I Psilopoulos; A Karameris; G Karvountzis
Journal:  J Hepatol       Date:  2001-06       Impact factor: 25.083

Review 2.  Interferons alpha and beta as immune regulators--a new look.

Authors:  C A Biron
Journal:  Immunity       Date:  2001-06       Impact factor: 31.745

Review 3.  Induction of clinical autoimmune disease by therapeutic interferon-alpha.

Authors:  Carmen Gota; Leonard Calabrese
Journal:  Autoimmunity       Date:  2003-12       Impact factor: 2.815

4.  Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells.

Authors:  Christian Mottet; Holm H Uhlig; Fiona Powrie
Journal:  J Immunol       Date:  2003-04-15       Impact factor: 5.422

5.  Antiapoptotic Mcl-1 is critical for the survival and niche-filling capacity of Foxp3⁺ regulatory T cells.

Authors:  Wim Pierson; Bénédicte Cauwe; Antonia Policheni; Susan M Schlenner; Dean Franckaert; Julien Berges; Stephanie Humblet-Baron; Susann Schönefeldt; Marco J Herold; David Hildeman; Andreas Strasser; Philippe Bouillet; Li-Fan Lu; Patrick Matthys; Antonio A Freitas; Rita J Luther; Casey T Weaver; James Dooley; Daniel H D Gray; Adrian Liston
Journal:  Nat Immunol       Date:  2013-07-14       Impact factor: 25.606

6.  Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus.

Authors:  Emily C Baechler; Franak M Batliwalla; George Karypis; Patrick M Gaffney; Ward A Ortmann; Karl J Espe; Katherine B Shark; William J Grande; Karis M Hughes; Vivek Kapur; Peter K Gregersen; Timothy W Behrens
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-25       Impact factor: 11.205

7.  Gene-targeted mice lacking the Trex1 (DNase III) 3'-->5' DNA exonuclease develop inflammatory myocarditis.

Authors:  Masashi Morita; Gordon Stamp; Peter Robins; Anna Dulic; Ian Rosewell; Geza Hrivnak; Graham Daly; Tomas Lindahl; Deborah E Barnes
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

8.  Type I IFNs regulate effector and regulatory T cell accumulation and anti-inflammatory cytokine production during T cell-mediated colitis.

Authors:  Abhisake Kole; JianPing He; Aymeric Rivollier; Danielle D Silveira; Kazuya Kitamura; Kevin J Maloy; Brian L Kelsall
Journal:  J Immunol       Date:  2013-08-02       Impact factor: 5.422

9.  Type I interferons directly inhibit regulatory T cells to allow optimal antiviral T cell responses during acute LCMV infection.

Authors:  Shivani Srivastava; Meghan A Koch; Marion Pepper; Daniel J Campbell
Journal:  J Exp Med       Date:  2014-04-07       Impact factor: 14.307

10.  Interferon and granulopoiesis signatures in systemic lupus erythematosus blood.

Authors:  Lynda Bennett; A Karolina Palucka; Edsel Arce; Victoria Cantrell; Josef Borvak; Jacques Banchereau; Virginia Pascual
Journal:  J Exp Med       Date:  2003-03-17       Impact factor: 14.307

View more
  4 in total

1.  IFN-α/β receptor signaling promotes regulatory T cell development and function under stress conditions.

Authors:  Amina Metidji; Sadiye Amcaoglu Rieder; Deborah Dacek Glass; Isabelle Cremer; George A Punkosdy; Ethan M Shevach
Journal:  J Immunol       Date:  2015-03-20       Impact factor: 5.422

2.  Pulmonary mucosal immunity mediated through CpG provides adequate protection against pulmonary Mycobacterium tuberculosis infection in the mouse model. A role for type I interferon.

Authors:  Amber Troy; Sandra C Esparza-Gonzalez; Alicia Bartek; Elizabeth Creissen; Linda Izzo; Angelo A Izzo
Journal:  Tuberculosis (Edinb)       Date:  2020-06-06       Impact factor: 3.131

Review 3.  Control of Regulatory T Cell Migration, Function, and Homeostasis.

Authors:  Daniel J Campbell
Journal:  J Immunol       Date:  2015-09-15       Impact factor: 5.422

4.  Type-I interferons in atherosclerosis.

Authors:  Hung-Jen Chen; Sander W Tas; Menno P J de Winther
Journal:  J Exp Med       Date:  2020-01-06       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.